Aurinia Pharmaceuticals Inc

As of June 30, 2026, Aurinia Pharmaceuticals Inc. carries a market capitalization of 1.98B, placing it among publicly traded companies globally. Its enterprise value stands at 1.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aurinia Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. has 132.91M shares outstanding.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 7.13. The price-to-sales ratio is 7.19, and the price-to-book ratio stands at 3.68.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 11.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.65B versus a market cap of 1.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.43, indicating elevated leverage, while an interest coverage ratio of 41.43 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aurinia Pharmaceuticals Inc. posted a return on equity (ROE) of 66.12, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 48.52, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.12M in revenue per employee across its workforce of 128.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.66 indicates how many times Aurinia Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Aurinia Pharmaceuticals Inc. recorded an income tax benefit of -134.58M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 140.37M, leaving 274.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Aurinia Pharmaceuticals Inc.'s stock has gained approximately 51.70% over the past 52 weeks. The 50-day moving average sits at 14.29, while the 200-day moving average is 13.49.

Over the twelve months ended June 30, 2026, Aurinia Pharmaceuticals Inc. generated 272.66M in revenue and converted that into 274.94M in net income, yielding earnings per share of 2.02. EBITDA reached 148.91M, while operating income came in at 131.95M.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. holds 387.87M in cash and equivalents against 56.14M in total debt, resulting in a net debt position of -157.41M. Total book value stands at 538.19M, with working capital of 386.38M providing operational flexibility.

Aurinia Pharmaceuticals Inc. produced 153.39M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -154,052.80 in capital expenditures, free cash flow totaled 153.24M - equivalent to 1.16 per share.

Over the twelve months ended June 30, 2026, Aurinia Pharmaceuticals Inc. posted a gross margin of 90.36, reflecting its pricing power and cost economics. The operating margin of 48.39 and net profit margin of 100.84 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 7.54, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.71, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aurinia Pharmaceuticals Inc. shareholders.

Aurinia Pharmaceuticals Inc.'s most recent stock split took place on October 23, 2013 with a 50:1 split ratio.

As of June 30, 2026, Aurinia Pharmaceuticals Inc. has an Altman Z-Score of 8.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.